Services on Demand
Journal
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Revista Medica Herediana
Print version ISSN 1018-130XOn-line version ISSN 1729-214X
Abstract
BARRIGA-SALAVERRY, Guillermo. Tomographic biomarkers in diabetic macular edema. Rev Med Hered [online]. 2022, vol.33, n.1, pp.56-63. Epub Mar 31, 2022. ISSN 1018-130X. http://dx.doi.org/10.20453/rmh.v33i1.4170.
Diabetic macular edema (DME) is the leading cause of decreased vision among diabetic patients. It can begin in any of the stages of diabetic retinopathy and be associated with comorbidities that can affect various body systems. Many times, the diabetic patient with macular edema needs multidisciplinary management through which he receives initial care from non-ophthalmologist specialists. There is evidence to support that early diagnosis and prompt treatment of DME can minimize permanent visual loss. Non-ophthalmologist specialists who care for diabetic patients can help to detect the DME that their patient may have early to receive the corresponding ophthalmological care. The purpose of this review is to provide the medical community with information on the contribution of optical coherence tomography in the diagnosis of DME and how to recognize tomographic biomarkers that allow predicting the visual outcome of its treatment.
Keywords : Optical Coherence Tomography; diagnosis; treatment outcome; predictive value of tests; diabetic retinopathy; vision disorders.